WO2002008456A3 - Verfahren zur identifizierung metastasierender tumorzellen - Google Patents

Verfahren zur identifizierung metastasierender tumorzellen Download PDF

Info

Publication number
WO2002008456A3
WO2002008456A3 PCT/EP2001/008517 EP0108517W WO0208456A3 WO 2002008456 A3 WO2002008456 A3 WO 2002008456A3 EP 0108517 W EP0108517 W EP 0108517W WO 0208456 A3 WO0208456 A3 WO 0208456A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cells
metastatic tumor
identifying
identifying metastatic
relates
Prior art date
Application number
PCT/EP2001/008517
Other languages
English (en)
French (fr)
Other versions
WO2002008456A8 (de
WO2002008456A2 (de
Inventor
Stein Oliver Von
Andrea Nestl
Martin Hofmann
Jonathan Sleeman
Peter Herrlich
Original Assignee
Karlsruhe Forschzent
Stein Oliver Von
Andrea Nestl
Martin Hofmann
Jonathan Sleeman
Peter Herrlich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlsruhe Forschzent, Stein Oliver Von, Andrea Nestl, Martin Hofmann, Jonathan Sleeman, Peter Herrlich filed Critical Karlsruhe Forschzent
Priority to CA002416697A priority Critical patent/CA2416697A1/en
Priority to EP01951701A priority patent/EP1356095A2/de
Priority to US10/333,872 priority patent/US20040265804A1/en
Priority to JP2002513938A priority patent/JP2004515221A/ja
Priority to AU2001272558A priority patent/AU2001272558A1/en
Publication of WO2002008456A2 publication Critical patent/WO2002008456A2/de
Publication of WO2002008456A8 publication Critical patent/WO2002008456A8/de
Publication of WO2002008456A3 publication Critical patent/WO2002008456A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Identifizierung und Behandlung von metastasierenden Tumorzellen, eine Population von cDNA-Sequenzen metastasespezifischer Gene zur Verwendung als Tumormarker zur Identifizierung von humanen Zellen und/oder Gewebe mit Metastasierungspotential und zur Therapie von Krebserkrankungen.
PCT/EP2001/008517 2000-07-25 2001-07-24 Verfahren zur identifizierung metastasierender tumorzellen WO2002008456A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002416697A CA2416697A1 (en) 2000-07-25 2001-07-24 Method for identifying metastasizing tumor cells
EP01951701A EP1356095A2 (de) 2000-07-25 2001-07-24 Verfahren zur identifizierung metastasierender tumorzellen
US10/333,872 US20040265804A1 (en) 2000-07-25 2001-07-24 Method for identifying metastatic tumor cells
JP2002513938A JP2004515221A (ja) 2000-07-25 2001-07-24 転移性腫瘍細胞の同定方法
AU2001272558A AU2001272558A1 (en) 2000-07-25 2001-07-24 Method for identifying metastatic tumor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10036126.9 2000-07-25
DE10036126 2000-07-25

Publications (3)

Publication Number Publication Date
WO2002008456A2 WO2002008456A2 (de) 2002-01-31
WO2002008456A8 WO2002008456A8 (de) 2002-07-11
WO2002008456A3 true WO2002008456A3 (de) 2003-09-04

Family

ID=7650102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008517 WO2002008456A2 (de) 2000-07-25 2001-07-24 Verfahren zur identifizierung metastasierender tumorzellen

Country Status (7)

Country Link
US (1) US20040265804A1 (de)
EP (1) EP1356095A2 (de)
JP (1) JP2004515221A (de)
AU (1) AU2001272558A1 (de)
CA (1) CA2416697A1 (de)
DE (1) DE10135996A1 (de)
WO (1) WO2002008456A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
DE10229391A1 (de) * 2002-06-29 2004-01-29 Forschungszentrum Karlsruhe Gmbh METASTACHIP: ein Biochip zur Bestimmung des metastatischen Potentials von Tumoren
DE10242663A1 (de) * 2002-09-13 2004-03-25 Forschungszentrum Karlsruhe Gmbh Verfahren zur Identifizierung von Inhibitoren in vivo

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (de) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Molekulare Markierungen
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504010B1 (en) * 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (de) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Molekulare Markierungen
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BROTHERICK I ET AL: "Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression.", CYTOMETRY: THE JOURNAL OF THE SOCIETY FOR ANALYTICAL CYTOLOGY. UNITED STATES 1 AUG 1998, vol. 32, no. 4, 1 August 1998 (1998-08-01), pages 301 - 308, XP001120360, ISSN: 0196-4763 *
DATABASE EMBL [online] XP002222689, Database accession no. S76054 *
DATABASE EMBL [online] XP002222690, Database accession no. M63482 *
HEMBROUGH T A ET AL: "A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines.", JOURNAL OF CELL SCIENCE. ENGLAND MAR 1995, vol. 108 ( Pt 3), March 1995 (1995-03-01), pages 1071 - 1082, XP002222686, ISSN: 0021-9533 *
HEMBROUGH T A ET AL: "Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.", THE BIOCHEMICAL JOURNAL. ENGLAND 1 AUG 1996, vol. 317 ( Pt 3), 1 August 1996 (1996-08-01), pages 763 - 769, XP002222684, ISSN: 0264-6021 *
HEMBROUGH TODD A ET AL: "Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 41, 1996, pages 25684 - 25691, XP002222685, ISSN: 0021-9258 *
HUDSON P J: "RECOMBINANT ANTIBODIES: A NOVEL APPROACH TO CANCER DIAGNOSIS AND THERAPY", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 6, June 2000 (2000-06-01), pages 1231 - 1242, XP001085133, ISSN: 1354-3784 *
VON STEIN O D ET AL: "A high throughput screening for rarely transcribed differentially expressed genes", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 25, no. 13, 1997, pages 2598 - 2602, XP002128671, ISSN: 0305-1048 *
YOKOTA J: "Tumor progression and metastasis.", CARCINOGENESIS. ENGLAND MAR 2000, vol. 21, no. 3, March 2000 (2000-03-01), pages 497 - 503, XP002222688, ISSN: 0143-3334 *

Also Published As

Publication number Publication date
WO2002008456A8 (de) 2002-07-11
EP1356095A2 (de) 2003-10-29
US20040265804A1 (en) 2004-12-30
JP2004515221A (ja) 2004-05-27
DE10135996A1 (de) 2002-03-28
CA2416697A1 (en) 2003-01-24
AU2001272558A1 (en) 2002-02-05
WO2002008456A2 (de) 2002-01-31

Similar Documents

Publication Publication Date Title
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP1515982A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO1999047669A3 (de) Menschliche nukleinsäuresequenzen aus brusttumorgewebe
HK1078585A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
EP1320376A4 (de) Behandlung von prostatakrebs
DE69942031D1 (de) In prostatakrebs exprimiertes gen
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU1186202A (en) Methods of inducing cancer cell death and tumor regression
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
WO2002008456A3 (de) Verfahren zur identifizierung metastasierender tumorzellen
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001241779A1 (en) Method of treatment of prostate cancer
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2001258575A1 (en) Treatment of cancer and neurological diseases
WO2000058464A3 (en) Rab genes and their uses
WO2004078123A3 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA DE JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

CFP Corrected version of a pamphlet front page
WWE Wipo information: entry into national phase

Ref document number: 2001951701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2416697

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001272558

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001951701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10333872

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001951701

Country of ref document: EP